TAILORED CLINICAL RESEARCH SOLUTIONS LIMITEDActive

Company number 09930195Private limited companyIncorporated 2015

Key figures

£107-99.9%
Net assets 2024
-76.8%
Average annual change 2020–2024
0200 k400 k600 k20202021202220232024

Like most small UK companies, TAILORED CLINICAL RESEARCH SOLUTIONS LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0500 k1 m20202021202220232024
Filed accounts2020–2024
20202021202220232024
Cash at bank and in hand145,581529,855228,063175,349133,945
Total assets153,381764,803561,860413,723221,941
Total liabilities123,349296,692359,512285,558230,883
Net assets / total equity36,997479,610215,857136,585107
Average number of employees671299

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: TAILORED CLINICAL RESEARCH SOLUTIONS LIMITED

Company

TAILORED CLINICAL RESEARCH SOLUTIONS LIMITED is a private limited company registered with Companies House under company number 09930195. It was incorporated on 29 Dec 2015. Its status is active. The registered office is in Oxford (OX2). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110), other human health activities (86900).

Accounts

The latest accounts in the database are for 2024 (period ending 31 Dec 2024); the company files small company accounts (filleted). Net assets were £107, down 99.9% on the previous year. Cash at bank and in hand was £133,945. Total assets were £221,941 and total liabilities £230,883. The company had an average of 9 employees. Figures are available for 5 financial years (2020–2024).

Control and charges

2 persons with significant control are registered.

Filing deadlines

The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 12 Jun 2027.